Absorption study of genistein using solid lipid microparticles and nanoparticles: Control of oral bioavailability by particle sizes

Biomolecules and Therapeutics

Volumn 25, Issue 4, 2017, Pages 452-459

  Kim, Jeong Tae ^a   Barua, Sonia ^a   Kim, Hyeongmin ^a   Hong, Seong Chul ^a   Yoo, Seung Yup ^a   Jeon, Hyojin ^a   Cho, Yeongjin ^a   Gil, Sangwon ^a   Oh, Kyungsoo ^a   Lee, Jaehwi ^a  

^a Chung Ang University   (South Korea)

Author keywords

Dissolution behavior; Genistein; Glyceryl palmitostearate; Oral bioavailability; Particle size; Solid lipid particles

Indexed keywords

DRUG CARRIER; GENISTEIN; GLYCEROL PALMITOSTEARATE; SOLID LIPID MICROPARTICLE; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RELEASE; DRUG SOLUBILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PARTICLE SIZE; POWDER; RAT; SUSPENSION;

EID: 85023600705     PISSN: 19769148     EISSN: 20054483     Source Type: Journal    
DOI: 10.4062/biomolther.2017.095     Document Type: Article

References (29)

1. Boyd, B. J., Khoo, S. M., Whittaker, D. V., Davey, G. and Porter, C. J. (2007) A lipid-based liquid crystalline matrix that provides sustained release and enhanced oral bioavailability for a model poorly water soluble drug in rats. Int. J. Pharm. 340, 52-60.
2. Desai, J. and Thakkar, H. (2016) Effect of particle size on oral bioavailability of darunavir-loaded solid lipid nanoparticles. J. Microencapsul. 33, 669-678.
3. Dingler, A. and Gohla, S. (2002) Production of solid lipid nanoparticles (SLN): scaling up feasibilities. J. Microencapsul. 19, 11-16.
4. Dixon, R. A. and Ferreira, D. (2002) Genistein. Phytochemistry 60, 205-211.
5. Drover, D. R., Angst, M. S., Valle, M., Ramaswamy, B., Naidu, S., Stanski, D. R. and Verotta, D. (2002) Input characteristics and bioavailability after administration of immediate and a new extended-release formulation of hydromorphone in healthy volunteers. Anesthesiology 97, 827-836.
6. Emami, J., Mohiti, H., Hamishehkar, H. and Varshosaz, J. (2015) Formulation and optimization of solid lipid nanoparticle formulation for pulmonary delivery of budesonide using Taguchi and Box-Behnken design. Res. Pharm. Sci. 10, 17-33.
7. Harde, H., Das, M. and Jain, S. (2011) Solid lipid nanoparticles: an oral bioavailability enhancer vehicle. Expert. Opin. Drug Deliv. 8, 1407-1424.
8. Horter, D. and Dressman, J. B. (2001) Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv. Drug Deliv. Rev. 46, 75-87.
9. Kumar, D. S. and Pandit, J. K. (1997) Relationship between dissolution rate and bioavailability of sustained-release ibuprofen capsules. Drug Dev. Ind. Pharm. 23, 987-992.
10. Kwon, S. H., Kim, S. Y., Ha, K. W., Kang, M. J., Huh, J. S., Im, T. J., Kim, Y. M., Park, Y. M., Kang, K. H., Lee, S., Chang, J. Y., Lee, J. and Choi, Y. W. (2007) Pharmaceutical evaluation of genistein-loaded pluronic micelles for oral delivery. Arch. Pharm. Res. 30, 1138-1143.
11. Lee, S. H., Kim, Y. H., Yu, H. J., Cho, N. S., Kim, T. H., Kim, D. C., Chung, C. B., Hwang, Y. I. and Kim, K. H. (2007) Enhanced bioavailability of soy isoflavones by complexation with beta-cyclodextrin in rats. Biosci. Biotechnol. Biochem. 71, 2927-2933.
12. Li, H. L., Zhao, X. B., Ma, Y. K., Zhai, G. X., Li, L. B. and Lou, H. X. (2009) Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. J. Control. Release 133, 238-244.
13. Li, Y., Sun, D., Palmisano, M. and Zhou, S. (2016) Slow drug delivery decreased total body clearance and altered bioavailability of immediateand controlled-release oxycodone formulations. Pharmacol. Res. Perspect. 4, e00210.
14. Luo, Y., Chen, D. W., Ren, L. X., Zhao, X. L. and Qin, J. (2006) Solid lipid nanoparticles for enhancing vinpocetine’s oral bioavailability. J. Control. Release 114, 53-59.
15. Mathot, F., Van Beijsterveldt, L., Preat, V., Brewster, M. and Arien, A. (2006) Intestinal uptake and biodistribution of novel polymeric micelles after oral administration. J. Control. Release 111, 47-55.
16. Mehnert, W. and Mader, K. (2001) Solid lipid nanoparticles: production, characterization and applications. Adv. Drug Deliv. Rev. 47, 165-196.
17. Muller, R. H., Mader, K. and Gohla, S. (2000) Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur. J. Pharm. Biopharm. 50, 161-177.
18. Muller, R. H., Runge, S., Ravell, V., Mehnert, W., Thunemann, A. F. and Souto, E. B. (2006) Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals. Int. J. Pharm. 317, 82-89.
19. Munish, A., Meenakshi, B. and Komal, S. (2016) Sodium alginate-arabinoxylan composite microbeads: preparation and characterization. J. Pharm. Investig. 46, 645-653.
20. Pankaj, V. D., Ritu, M. G. and Shashikant, N. D. (2016) Formulation and development of solid self micro-emulsifying drug delivery system (S-SMEDDS) containing chlorthalidone for improvement of dissolution. J. Pharm. Investig. 46, 633-644.
21. Reithmeier, H., Herrmann, J. and Gopferich, A. (2001) Lipid microparticles as a parenteral controlled release device for peptides. J. Control. Release 73, 339-350.
22. Scalia, S., Young, P. M. and Traini, D. (2015) Solid lipid microparticles as an approach to drug delivery. Expert. Opin. Drug Deliv. 12, 583-599.
23. Shelnutt, S. R., Cimino, C. O., Wiggins, P. A., Ronis, M. J. and Badger, T. M. (2002) Pharmacokinetics of the glucuronide and sulfate conjugates of genistein and daidzein in men and women after consumption of a soy beverage. Am. J. Clin. Nutr. 76, 588-594.
24. Takeuchi, H., Matsui, Y., Yamamoto, H. and Kawashima, Y. (2003) Mucoadhesive properties of carbopol or chitosan-coated liposomes and their effectiveness in the oral administration of calcitonin to rats. J. Control. Release 86, 235-242.
25. Tang, J., Xu, N., Ji, H., Liu, H., Wang, Z. and Wu, L. (2011) Eudragit nanoparticles containing genistein: formulation, development, and bioavailability assessment. Int. J. Nanomedicine 6, 2429-2435.
26. Tripathi, S., Kushwah, V., Thanki, K. and Jain, S. (2016) Triple antioxidant SNEDDS formulation with enhanced oral bioavailability: Implication of chemoprevention of breast cancer. Nanomedicine 12, 1431-1443.
27. Uner, M. and Yener, G. (2007) Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int. J. Nanomedicine 2, 289-300.
28. Yang, Z., Kulkarni, K., Zhu, W. and Hu, M. (2012) Bioavailability and Pharmacokinetics of Genistein: Mechanistic Studies on its ADME. Anticancer Agents Med. Chem. 12, 1264-1280.
29. Zhang, Y., Song, T. T., Cunnick, J. E., Murphy, P. A. and Hendrich, S. (1999) Daidzein and genistein glucuronides in vitro are weakly estrogenic and activate human natural killer cells at nutritionally relevant concentrations. J. Nutr. 129, 399-405.